EyePoint Pharmaceuticals Inc EYPT

NAS: EYPT | ISIN: US30233G1004 30/04/2025

6,820 USD (+2,71%)

(+2,71%) 30/04/2025

Toon enkel gratis nieuws

28 januari 2023 · Eyepoint Shareholder Action Reminder · Persbericht

22 januari 2023 · EYEPOINT INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Eyepoint To Contact Him Directly To Discuss Their Options · Persbericht

1 augustus 2022 · EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Maintenance Treatment of Wet AMD · Persbericht

15 juli 2022 · EyePoint Pharmaceuticals Announces Positive 12-Month Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD · Persbericht

12 februari 2022 · EyePoint Pharmaceuticals Announces Updated Positive Interim Safety and Efficacy Data from Ongoing Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD · Persbericht

13 november 2021 · EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD · Persbericht

13 november 2021 · EyePoint Pharmaceuticals Reports Positive Interim Safety and Efficacy Data from Phase 1 DAVIO Clinical Trial Evaluating EYP-1901 for the Treatment of Wet AMD · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe